common
cold
frequent
infect
worldwid
adult
report
two
four
cold
year
children
six
eight
cold
median
incub
period
depend
viru
usual
sever
symptom
typic
peak
day
symptom
almost
alway
selflimit
ill
total
symptom
durat
histor
estim
put
total
cost
common
cold
usa
high
billion
per
includ
healthcar
resourc
use
work
product
loss
latter
approach
one
half
common
cold
caus
human
rhinoviru
hrv
although
autumn
hrv
may
account
upper
respiratori
tract
hrv
strongli
associ
exacerb
asthma
children
adult
caus
sever
longlast
symptom
patient
respiratori
virus
includ
hrv
found
exacerb
patient
chronic
obstruct
pulmonari
diseas
copd
treatment
common
cold
support
symptomat
twothird
cold
use
counter
treatment
shown
benefit
treatment
common
cold
includ
echinacea
antihistamin
intranas
corticosteroid
antivir
regular
supplement
vitamin
c
small
effect
cold
durat
therapeut
supplement
symptom
develop
lack
evid
unlik
supplement
lowdos
vitamin
c
symptomat
reduc
symptom
sever
durat
effect
hrv
vaccin
part
high
sequenc
variabl
antigen
site
distinct
hrv
steam
inhal
symptom
relief
tradit
remedi
common
cold
scientif
rational
treatment
hrv
temperaturesensit
viru
temperaturedepend
reduct
viral
replic
host
defenc
may
also
enhanc
higher
temperatur
mechan
greater
product
respons
enhanc
antivir
immun
respons
mediat
heat
shock
clinic
studi
efficaci
heat
humidifi
air
deliv
high
flow
upper
airway
rhinothermi
report
inconsist
studi
limit
includ
variabl
like
ineffect
method
deliv
heat
humid
air
high
flow
upper
airway
method
includ
deliveri
nozzl
held
distanc
away
nare
vent
anaesthet
mask
report
intervent
durat
also
variabl
cochran
review
assess
current
evid
could
support
refut
effect
recommend
need
robustli
design
adequ
power
randomis
control
trial
rct
assess
effect
rhinothermi
treat
common
report
toler
studi
found
high
flow
nasal
cannula
devic
myairvo
fisher
paykel
healthcar
auckland
new
zealand
modifi
deliv
high
flow
humidifi
air
via
wide
bore
nasal
cannula
well
toler
healthi
potenti
advantag
devic
rhinothermi
deliv
consist
temperatur
humid
flow
rate
direct
upper
airway
studi
report
feasibl
studi
rhinothermi
treatment
common
cold
inform
design
robust
rct
treatment
specif
aim
feasibl
studi
estim
proport
potenti
particip
screen
undergo
randomis
complet
studi
turn
provid
estim
time
resourc
requir
undertak
rct
estim
sd
propos
primari
outcom
variabl
rct
modifi
jackson
sampl
size
rct
better
estim
estim
like
minimum
clinic
import
differ
mcid
modifi
jackson
score
among
peopl
common
cold
elig
take
part
studi
estim
proport
differ
virus
caus
cold
among
peopl
common
cold
elig
take
part
studi
examin
use
toler
modifi
myairvo
devic
common
cold
openlabel
randomis
control
feasibl
studi
particip
selfreport
symptom
common
cold
recruit
commun
advertis
wellington
hospit
new
zealand
notic
board
intranet
local
primari
care
practic
pharmaci
student
notic
board
social
media
medic
research
institut
new
zealand
databas
particip
elig
year
old
common
cold
symptom
less
hour
time
randomis
modifi
jackson
score
modifi
jackson
score
calcul
symptom
sever
questionnair
consist
eight
symptom
sneez
nasal
discharg
nasal
congest
sorescratchi
throat
cough
headach
malais
feverchil
score
scale
total
score
rang
particip
recruit
immunosuppress
medic
condit
andor
prescrib
immunosuppress
medic
diagnosi
asthma
copd
signific
respiratori
condit
nasal
condit
deviat
septum
chronic
rhiniti
could
impair
nasal
breath
use
cold
remedi
exampl
decongestantscough
medicin
linctusthroat
lozeng
within
hour
randomis
current
use
antibiot
inhal
medic
known
allergi
ascorb
acid
vitamin
c
investig
believ
particip
caregiv
would
unabl
safe
use
myairvo
devic
without
medic
supervis
condit
investig
discret
believ
may
present
safeti
risk
impact
feasibl
studi
studi
result
studi
prospect
regist
australian
new
zealand
clinic
trial
registri
trial
id
studi
sponsor
fisher
paykel
healthcar
manufactur
myairvo
devic
written
inform
consent
obtain
start
studi
specif
procedur
studi
particip
abl
stop
intervent
time
without
withdrawn
studi
particip
also
abl
withdraw
studi
time
without
give
reason
particip
randomli
assign
ratio
two
group
receiv
either
rhinothermi
via
modifi
myairvo
devic
hour
per
day
day
control
medic
vitamin
c
mg
healtheri
vitaco
health
nz
auckland
new
zealand
daili
day
randomis
schedul
comput
gener
studi
statistician
involv
studi
recruit
procedur
data
collect
randomis
administ
preseal
opaqu
envelop
open
point
randomis
investig
investig
blind
alloc
point
due
natur
intervent
unequ
randomis
design
particip
investig
studi
statistician
could
mask
treatment
alloc
demograph
data
collect
baselin
common
cold
symptom
record
use
modifi
jackson
score
physic
examin
carri
doctor
elig
confirm
pernas
flock
swab
copan
diagnost
california
usa
collect
univers
transport
medium
roch
diagnost
basel
switzerland
amplif
sampl
underw
nucleic
acid
detect
use
multiplex
revers
transcriptasepcr
roch
diagnost
basel
switzerland
conjunct
respiratori
pathogen
kit
fasttrack
diagnost
junglinst
luxembourg
allow
detect
present
influenza
influenza
influenza
b
rhinoviru
coronaviru
parainfluenza
human
metapneumoviru
ab
human
bocaviru
respiratori
syncyti
viru
ab
adenoviru
enteroviru
parechoviru
mycoplasma
pneumonia
intervent
group
receiv
rhinothermi
via
modifi
myairvo
devic
fisher
paykel
healthcar
heat
breath
tube
chamber
fisher
paykel
healthcar
optiflownas
cannula
fisher
paykel
healthcar
see
figur
system
humidifi
integr
flow
gener
abl
humidifi
respiratori
gase
deliv
heat
breath
tube
nasal
cannula
interfac
randomis
particip
alloc
intervent
group
use
myairvo
inhal
humidifi
air
lmin
continu
hour
supervis
investig
clinic
trial
unit
ctu
wellington
hospit
wellington
new
zealand
train
myairvo
setup
use
particip
given
modifi
myairvo
devic
use
home
accord
regimen
humid
lmin
min
day
depend
resolut
symptom
particip
encourag
use
devic
least
hour
per
day
longer
desir
either
singl
repeat
administr
prefer
even
particip
allow
reduc
flow
lmin
lmin
accord
comfort
home
day
particip
randomis
myairvo
group
contact
phone
check
advers
event
andor
problem
use
myairvo
particip
alloc
control
group
receiv
first
mg
vitamin
c
tablet
ctu
randomis
home
day
lowdos
vitamin
c
use
control
therapeut
use
vitamin
c
symptom
develop
shown
consist
reduc
durat
cold
improv
cold
particip
expect
deriv
benefit
obtain
placebo
effect
low
dose
vitamin
c
use
studi
freeli
avail
pharmaci
new
zealand
unlik
benefit
taken
symptom
develop
oppos
regular
supplement
particip
use
vitamin
c
return
bottl
medicin
reconcili
particip
request
complet
symptom
diari
everi
day
day
diari
compris
daili
modifi
jackson
score
questionnair
box
tick
first
felt
lot
better
compar
studi
entri
mean
chang
modifi
jackson
score
particip
felt
lot
better
use
estim
mcid
particip
return
clinic
second
final
visit
day
return
symptom
diari
particip
use
myairvo
return
devic
ask
fill
toler
questionnair
experi
nine
question
particip
record
answer
continu
scale
posit
least
posit
question
teach
session
connect
compon
clean
process
level
comfort
amount
moistur
devic
weight
nasal
interfac
noisi
appli
remov
nasal
interfac
likelihood
reus
futur
complianc
data
myairvo
upload
analys
primari
outcom
measur
proport
recruit
randomis
outcom
measur
includ
proport
randomis
particip
complet
studi
mean
sd
modifi
jackson
score
randomis
day
initi
randomis
regimen
time
feel
lot
better
compar
studi
entri
time
resolut
symptom
symptom
score
day
postrandomis
proport
organ
identifi
pcr
analysi
nasal
swab
taken
baselin
pattern
use
myairvo
devic
determin
electron
monitor
capabl
myairvo
estim
adher
control
group
myairvo
toler
questionnair
result
sampl
size
chosen
assess
proport
screen
particip
randomis
trial
minimum
patient
approach
assum
recruit
rate
less
achiev
particip
particip
power
one
side
alpha
rule
recruit
rate
less
estim
sd
chang
baselin
modifi
jackson
score
sampl
size
least
accept
precis
estim
sd
base
distribut
estim
minimum
clinic
import
differ
jackson
score
would
requir
minimum
particip
precis
base
statist
recruit
complet
rate
ci
estim
clopperpearson
exact
method
mix
linear
model
exponentialintim
covari
matrix
use
estim
differ
modifi
jackson
score
treatment
time
post
hoc
interact
term
test
respons
modifi
jackson
score
differ
whether
nasal
swab
result
posit
ci
sd
chang
baselin
modifi
jackson
score
estim
use
distribut
logist
regress
use
estim
receiv
oper
characterist
curv
probabl
particip
first
say
lot
better
compar
chang
baselin
modifi
jackson
score
particular
time
time
measur
chosen
half
particip
report
improv
time
point
individu
sensit
specif
calcul
chang
baselin
modifi
jackson
score
time
surviv
analysi
use
estim
relationship
treatment
time
particip
said
felt
better
time
modifi
jackson
score
zero
kaplanmei
plot
surviv
cox
proport
hazard
regress
estim
differ
surviv
note
shorter
surviv
better
analysi
event
time
feel
better
sa
use
studi
data
collect
manag
use
redcap
electron
data
captur
tool
host
medic
research
institut
new
patient
public
involv
set
research
question
develop
outcom
measur
involv
develop
plan
design
implement
studi
patient
public
ask
advis
interpret
write
result
burden
intervent
patient
assess
result
research
dissemin
studi
particip
wish
notifi
particip
flow
studi
shown
figur
potenti
particip
screen
elig
particip
randomis
particip
complet
visit
may
juli
particip
predominantli
young
adult
nonsmok
tabl
recruit
rate
ci
one
main
reason
exclus
particip
symptom
hour
longer
present
figur
randomis
particip
complet
studi
result
retent
rate
lower
confid
limit
particip
symptom
mean
hour
present
time
mean
modifi
jackson
score
tabl
particip
complet
modifi
jackson
score
day
tabl
show
mean
sd
median
iqr
rang
modifi
jackson
score
baselin
day
group
mean
chang
modifi
jackson
score
baselin
greater
rhinothermi
group
control
group
hour
remain
greater
control
group
day
tabl
onlin
supplementari
tabl
figur
show
plot
chang
baselin
modifi
jackson
score
total
particip
report
feel
lot
better
within
day
randomis
particip
rhinothermi
group
control
group
particip
two
particip
fill
modifi
jackson
score
day
felt
lot
better
therefor
estim
mcid
use
score
particip
rhinothermi
group
control
group
recognis
post
hoc
threshold
lot
better
correspond
estim
substanti
clinic
benefit
rather
estim
chang
repres
substanti
clinic
benefit
chang
baselin
modifi
jackson
score
best
sensit
specif
particip
state
felt
lot
better
unit
modifi
jackson
score
day
tabl
base
analysi
propos
chang
modifi
jackson
score
substanti
clinic
benefit
threshold
instrument
differ
modifi
jackson
score
rhinothermi
group
control
group
greater
substanti
clinic
benefit
threshold
day
p
tabl
complet
resolut
symptom
denot
modifi
jackson
score
zero
occur
particip
within
day
randomis
particip
complet
modifi
jackson
score
day
rhinothermi
group
vitamin
c
group
hr
ci
feel
lot
better
rhinothermi
compar
control
favour
rhinothermi
group
kaplanmei
base
surviv
curv
shown
figur
report
advers
event
sd
modifi
jackson
score
day
base
pool
valu
ttest
ci
chang
baselin
modifi
jackson
score
ci
posit
nasal
swab
pcr
respiratori
viru
found
particip
organ
found
shown
tabl
hrv
commonli
detect
viru
found
onethird
particip
evid
interact
treatment
differ
modifi
jackson
score
nasal
swab
posit
neg
time
point
mean
total
use
myairvo
devic
hour
mean
sd
hour
per
day
eight
particip
use
myairvo
devic
day
seven
particip
use
less
day
day
myairvo
use
mean
sd
use
hour
per
day
particip
control
group
took
five
vitamin
c
tablet
per
protocol
adher
day
clinic
particip
use
flow
lmin
day
particip
kept
use
flow
rate
home
particip
use
reduc
flow
flow
lmin
lmin
use
particip
respect
day
mixtur
three
differ
flow
rate
use
mean
flow
rate
overal
around
lmin
toler
questionnair
result
myairvo
shown
tabl
devic
reason
simpl
connect
home
comfort
wear
accept
regard
amount
moistur
buildup
weight
nasal
interfac
also
score
favour
respect
eas
applic
found
moder
noisi
overal
particip
score
mean
sd
unit
scale
like
futur
use
like
unlik
studi
shown
rct
rhinothermi
via
high
flow
nasal
cannula
treatment
common
cold
feasibl
studi
fulli
recruit
particip
within
period
complet
studi
adher
rhinothermi
treatment
good
particip
symptomat
first
studi
investig
rhinothermi
use
modifi
myairvo
devic
strength
includ
randomis
control
design
complet
followup
particip
particip
studi
recruit
primarili
social
media
result
generalis
peopl
commun
symptom
common
cold
three
main
limit
appli
result
first
studi
design
feasibl
studi
mean
although
modifi
jackson
score
prespecifi
efficaci
outcom
measur
formal
specifi
primari
outcom
measur
second
due
natur
intervent
unabl
blind
particip
investig
alloc
intervent
futur
studi
aim
replic
result
explor
option
sham
rhinothermi
final
small
sampl
size
mean
although
studi
found
benefit
new
treatment
result
rel
fragil
modifi
jackson
score
would
need
chang
small
number
particip
receiv
rhinothermi
intervent
match
control
group
conclus
formal
fragil
index
calcul
chang
modifi
jackson
score
dichotom
variabl
complet
followup
particip
help
protect
fragil
howev
due
limit
larger
replic
studi
requir
develop
myairvo
devic
capac
deliv
humidifi
air
high
flow
direct
upper
airway
wide
bore
nasal
cannula
present
opportun
investig
efficaci
rhinothermi
lack
rct
year
pragmat
regimen
use
studi
base
avail
vitro
vivo
studi
temperatur
use
although
dose
depend
reduct
hrv
replic
temperatur
temperatur
around
prone
caus
minor
mucos
twohour
session
use
due
evid
shortest
durat
inhibit
hrv
replic
observ
min
rather
min
hyperthermia
repeat
session
administ
day
vitro
effect
hyperthermia
transient
hrv
yield
hypertherm
treat
cell
reach
baselin
level
within
rhinothermi
regimen
well
toler
particip
report
comfort
easi
use
appli
although
somewhat
noisi
similar
observ
made
earlier
toler
myairvo
devic
healthi
current
studi
particip
use
myairvo
devic
hour
per
day
averag
throughout
treatment
period
hour
day
use
instruct
particip
use
devic
late
treatment
cours
symptom
improv
around
third
particip
reduc
flow
rate
lmin
lmin
suggest
give
particip
option
reduc
flow
initi
lmin
lower
start
flow
worthwhil
although
primari
outcom
studi
rhinothermi
modifi
myairvo
devic
reduc
common
cold
symptom
compar
lowdos
vitamin
c
treatment
differ
randomis
group
observ
within
hour
efficaci
singl
dose
regimen
session
period
day
may
enhanc
implement
clinic
practic
worth
studi
howev
altern
rhinothermi
regimen
need
assess
studi
find
suggest
regimen
use
feasibl
studi
also
use
futur
rct
studi
also
inform
term
like
number
particip
requir
rct
estim
chang
modifi
jackson
score
denot
substanti
clinic
benefit
chang
base
largest
confid
limit
sd
upper
ci
jackson
score
day
sampl
size
group
allow
detect
differ
unit
power
type
error
rate
allow
dropout
rate
total
particip
would
need
randomis
group
would
requir
total
particip
rct
investig
two
randomis
treatment
specif
respiratori
viru
identifi
pcr
particip
major
rhinoviru
respiratori
viru
detect
rate
compar
previou
studi
report
detect
rate
found
differ
treatment
effect
particip
nasal
swab
pcr
posit
neg
indic
find
generalis
symptomat
common
cold
restrict
posit
viru
detect
also
suggest
efficaci
may
also
relat
nontemperaturerel
antivir
effect
humidif
airway
enhanc
mucociliari
clearanc
studi
show
rct
rhinothermi
modifi
myairvo
devic
feasibl
rhinothermi
well
toler
estim
chang
denot
substanti
clinic
benefit
modifi
jackson
score
chang
observ
rhinothermi
improv
symptom
requir
replic
larger
studi
common
cold
investig
efficaci
rhinothermi
treatment
influenza
also
prioriti
view
temperaturesensit
influenza
major
public
health
burden
influenza
